Reviva Pharmaceuticals Holdings, Inc. Number of Reportable Segments
Reviva Pharmaceuticals Holdings, Inc. (RVPH) reported Number of Reportable Segments of 100.00% for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Notes › Segment Reporting
us-gaap:NumberOfReportableSegments · last filed 2026-08-12
- Reviva Pharmaceuticals Holdings, Inc. number of reportable segments for the quarter ending 2026-03-31 was 100.00%.
- Reviva Pharmaceuticals Holdings, Inc. number of reportable segments for fiscal 2025 was 100.00%.
| Period end | Number of Reportable Segments 3 month | Number of Reportable Segments 6 month | Number of Reportable Segments 9 month | Number of Reportable Segments 12 month |
|---|---|---|---|---|
| 2026-06-30 | 100.00% 10-Q · filed 2026-08-12 | |||
| 2026-03-31 | 100.00% 10-Q · filed 2026-05-13 | |||
| 2025-12-31 | 100.00% 10-K · filed 2026-03-30 | |||
| 2025-09-30 | 100.00% 10-Q · filed 2025-11-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| REVELATION BIOSCIENCES, INC. (REVB) | United States | $0.004B | |
| HCW Biologics Inc. (HCWB) | United States | $0.004B | -6.15 |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |